1887

oa Southern African Journal of Gynaecological Oncology - Modelling research shows -induced immune response may be prolonged for at least 20 years for both HPV 16 and 18 : press release

 

Abstract

Results of three statistical models presented recently at the European Research Organisation on Genital Infection and Neoplasia (EUROGIN) annual meeting in Nice suggest that young women vaccinated with GlaxoSmithKline's HPV vaccine could look forward to a prolonged immune response against the two most common cancer-causing human papillomavirus virus (HPV), types HPV 16 and 18 for at least 20 years.

Loading

Article metrics loading...

/content/mp_sajgo/1/1/EJC80952
2009-01-01
2016-12-06
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error